Medical hypnosis on depression and interleukin-6 levels in lung cancer patients

Wijaya Kusuma; Ardi Andriatno; Budhi Hami Seno

doi:10.18203/2320-6012.ijrms20241602

Authors

Wijaya Kusuma Department of Psychiatric Medicine in University of Sebelas Maret, Surakarta, Indonesia
Ardi Andriatno Department of Psychiatric Medicine in University of Sebelas Maret, Surakarta, Indonesia
Budhi Hami Seno Department of Psychiatric Medicine in University of Sebelas Maret, Surakarta, Indonesia

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241602

Keywords:

Medical hypnosis, Lung cancer patients, Depression, Interleukin-6 levels

Abstract

Background: Lung cancer patients are at high risk for depression, which is associated with poor treatment adherence. Medical hypnosis can improve symptoms of depression and affect interleukin-6 levels. This study aims to determine the effectiveness of medical hypnosis in improving depression and reducing IL-6 levels in lung cancer patients.

Methods: This study is a quasi-experimental study with a pretest and post-test control group design. It assessed depressive symptoms using BDI-II scores and serum IL-6 levels in an intervention group receiving medical hypnosis and standard therapy compared to a control group receiving standard therapy. Data analysis was conducted using univariate tests, followed by Pearson correlation tests and effect size measurement with Cohen's d test.

Results: The Wilcoxon test showed a decrease in IL-6 levels in the intervention group by 14.66±19.45 (p=0.008) and a reduction in BDI-II scores by 8.26±4.78 (p=0.001). Correlation tests indicated a significant relationship between IL-6 levels and BDI-II scores (r=0.472; p=0.009). Cohen's d test showed the effect size of medical hypnosis on IL-6 levels was 0.754 (moderate=0.5<ES<0.8).

Conclusions: Medical hypnosis is effective in improving depressive symptoms and reducing IL-6 levels in lung cancer patients.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3): 209-49.

Lee Y, Hung CF, Chien CY, Lin PY, Lin MC, Wang CC, et al. Comparison of prevalence and associated factors of depressive disorder between patients with head and neck cancer and those with lung cancer at a tertiary hospital in Taiwan: A cross-sectional study. BMJ. 2020;10(6):23-9.

Hung MS, Chen IC, Lee CP, Huang RJ, Chen PC, Tsai YH, et al. Incidence and risk factors of depression after diagnosis of lung cancer. Medicine (United States). 2017;96(19):32-8.

Shahedah KK, How SH, Jamalludin AR, Faiz MTM, Kuan YC, Ong CK. Depressive symptoms in newly diagnosed lung carcinoma: Prevalence and associated risk factors. Tuberc Respir Dis. 2019; 82(3):217-26.

Yan J, Chen Y, Luo M, Hu X, Li H, Liu Q, et al. Chronic stress in solid tumor development: from mechanisms to interventions. J Biomed Sci. 2023; 30:3-9.

Fraile-Martinez O, Alvarez-Mon MA, Garcia-Montero C, Pekarek L, Guijarro LG, Lahera G, et al. Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine. Front Oncol. 2022;12:42-8.

Liu M, Li Y, Liu X. Serum tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-17 relate to anxiety and depression risks to some extent in non-small cell lung cancer survivor. Clin Respir J. 2022;16(2):105-15.

Liu WJ, Wang XD, Wu W, Huang X. Relationship between depression and blood cytokine levels in lung cancer patients. Med Sci. 2018;34:113-5.

Dubinett SM. Inflammation and lung cancer. Inflammation and Lung Cancer. New York: Springer; 2015:1-212.

Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018.

Császár N, Scholkmann F, Bókkon I. Implications on hypnotherapy: Neuroplasticity, epigenetics and pain. Neurosci Biobehav Rev. 2021;131:755-64.

Haipt A, Rosenbaum D, Fuhr K, Giese M, Batra A, Ehlis AC. The effects of hypnotherapy compared to cognitive behavioral therapy in depression: a NIRS-study using an emotional gait paradigm. Eur Arch Psychiatry Clin Neurosci. 2022;272(4):729-39.

Häuser W, Hagl M, Schmierer A, Hansen E. The Efficacy, Safety and Applications of Medical Hypnosis: A Systematic Review of Meta-Analyses. Dtsch Arztebl Int. 2016;113(17):289-96.

Fuhr K, Meisner C, Broch A, Cyrny B, Hinkel J, Jaberg J, et al. Efficacy of hypnotherapy compared to cognitive behavioral therapy for mild to moderate depression - Results of a randomized controlled rater-blind clinical trial. J Affect Disord. 2021;286: 166-73.

Eaton LH, Beck SL, Jensen MP. An Audio-Recorded Hypnosis Intervention for Chronic Pain Management in Cancer Survivors: A Randomized Controlled Pilot Study. Int J Clin Exp Hypn. 2021; 69(4):422-40.

Schoen M, Nowack K. Reconditioning the stress response with hypnosis CD reduces the inflammatory cytokine IL-6 and influences resilience: A pilot study. Complement Ther Clin Pract. 2013;19(2):83-8.

McCann BS, Landes SJ. Hypnosis in the treatment of depression: Considerations in research design and methods. Int J Clin Exp Hypn. 2010;58:147-64.

Yapko MD. Essentials of Hypnosis. 2nd ed. New York: Routledge; 2015,

Polityńska B, Pokorska O, Wojtukiewicz AM, Sawicka M, Myśliwiec M, Honn KV, et al. Is depression the missing link between inflammatory mediators and cancer? Pharmacol Ther. 2022;240: 108.

Lee ARY, Leong I, Lau G, Tan AW, Ho RCM, Ho CSH, et al. Depression and anxiety in older adults with cancer: Systematic review and meta-summary of risk, protective and exacerbating factors. Gen Hosp Psychiatr. 2023;81:32-42.

Shah A, Pataki CS, Sussman N. Synopsis of Psychiatry. 12th ed. Philadelphia: Wolters Kluwer; 2022:1215-82.

Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatr. 2023;28: 284-97.

Fontanelli L, Spina V, Chisari C, Siciliano G, Santarcangelo EL. Is hypnotic assessment relevant to neurology? Neurol Sci. 2022;43:4655-61.

Milling LS, Valentine KE, McCarley HS, LoStimolo LM. A Meta-Analysis of Hypnotic Interventions for Depression Symptoms: High Hopes for Hypnosis? Am J Clin Hypn. 2018;61(3): 227-43.

Tang HT, Zhang YP, Zhao S, Song C. Common mechanisms involved in lung cancer and depression: The dominant role of interleukin-6-IDO pathway in the lung-brain axis. J Affect Disord Rep. 2023;12: 100.

Wang D, He N, Liu Y, Pang R, Dilixiati M, Wumaier A. Influencing factors of depressive symptoms in patients with malignant tumour. J Int Med Res. 2021;49(12):3.

Rahariyani LD. Lama sakit dan proses berduka pada pasien kanker. J Keperawatan. 2017;10(1):6-10.

Tian H, Hu Z, Xu J, Wang C. The molecular pathophysiology of depression and the new therapeutics. Med Comm. 2022;3:156.

Mullon JJ, Olson EJ. Clinical diagnosis and basic evaluation. In: Hansen H, editor. Textbook of Lung Cancer. 2nd ed. London: Informa Healthcare; 2008: 75-86.

Riedl D, Schüßler G. Factors associated with and risk factors for depression in cancer patients – A systematic literature review. Transl Oncol. 2022;16: 101.